RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies

• Status: Recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T/NK-cell hematologic malignancies. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: He Huang

Criteria

Inclusion Criteria:

1. Aged 3 to 70 years.

2. Diagnosis of r/r T-ALL/NK-ALL, T-LBL, or T-NHL (including PTCL-NOS, AITL, ALCL, Extranodal NK/T cell lymphoma).

3. ECOG: 0-2.

4. Life expectancy greater than 12 weeks.

5. Cardiac left ventricle ejection fraction ≥50%.

6. Informed consent explained to, understood by and signed by the patient/guardian. Patient/guardian is given a copy of informed consent.

Exclusion Criteria:

1. Pregnant or lactating.

2. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection is not within the normal range; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C Viral (HCV) RNA positive; human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA positive; syphilis positive.

3. Patients with graft-versus-host disease (GVHD) or who need to use immunosuppressive drugs.

4. Participated in other clinical studies within 2 weeks prior to screening.

5. History of alcoholism, drug abuse or mental illness.

6. Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.